Testing an endoscopic treatment for pancreatic cancer that can't be removed
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic ductal adenocarcinoma confirmed by biopsy (tissue sample).
- Imaging (CT or MRI) shows a pancreatic tumor between 1 cm and 4 cm.
- The cancer is locally advanced and cannot be removed by surgery, with no distant spread on scans.
- You can do normal activities with some limits (ECOG performance status 0 to 2).
- The tumor can be reached through the endoscope (endoscopically accessible).
- You are not pregnant and can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how safe and effective endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is for treating pancreatic growths that might become cancer or already are cancer. It is for people who are already scheduled to have this procedure as part of their care.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy helps treat pancreatic cancer that is borderline or locally advanced and cannot be removed by surgery right away. It may shrink the tumor enough to allow surgery later.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.